Isis earns $18m milestone payment from GSK for advancing ISIS-TTR
ISIS-TTR is an antisense drug intends for the treatment of transthyretin amyloidosis, a genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. For the ISIS-TTR
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.